Form 4: BridgeBio Pharma Director Receives Significant Equity Grants

BridgeBio Pharma, Inc. Director James C. Momtazee was granted 6,589 restricted stock units and 8,425 stock options, aligning his interests with long-term company performance.

Summary

• James C. Momtazee, a Director of BridgeBio Pharma, Inc. (BBIO), reported an acquisition of equity securities.
• On June 20, 2025, Mr. Momtazee was granted 6,589 Restricted Stock Units (RSUs) under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.
• Each RSU represents a contingent right to receive one share of the Issuer's Common Stock, with a grant price of $0.
• These RSUs will vest one-third each year after June 20, 2025, with full vesting by June 20, 2028, contingent on his continued service on the board.
• Following this transaction, Mr. Momtazee beneficially owns 95,080 shares of Common Stock directly.
• Additionally, on June 20, 2025, Mr. Momtazee was granted 8,425 stock options with an exercise price of $41.73 per share and a grant price of $0.
• These stock options will also vest one-third each year after June 20, 2025, fully vesting by June 20, 2028, subject to his continued board service.
• The stock options have an expiration date of June 19, 2035.
• Following this transaction, Mr. Momtazee beneficially owns 8,425 stock options directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects standard, long-term incentive compensation for a director, aligning their interests with the company's performance. It's a routine transaction rather than a significant positive or negative event.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with the long-term performance and shareholder value of BridgeBio Pharma, Inc.
• The multi-year vesting schedule (one-third per year over three years) encourages continued service and commitment from the director.

Negatives

• The issuance of new equity (RSUs and options) could lead to minor dilution for existing shareholders upon vesting and exercise, although this is standard for equity compensation.

Risks

• Vesting of both the RSUs and stock options is subject to the reporting person's continued service on the Issuer's board of directors, meaning the benefits are contingent on ongoing engagement.

Future Outlook

The vesting schedules for both the RSUs and stock options extend to June 20, 2028, indicating an expectation of continued service from Director James C. Momtazee on the BridgeBio Pharma, Inc. board.

Industry Context

This filing represents a routine equity compensation grant to a director, a common practice across various industries, particularly in biotechnology and pharmaceutical sectors, to incentivize long-term commitment and align leadership interests with shareholder value.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of equity securities by BridgeBio Pharma, Inc. to James C. Momtazee, a director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the issuance of new shares upon vesting and exercise, but also benefit from increased alignment of director interests with long-term company performance.
• Employees: No direct impact mentioned, but reflects the company's general approach to equity-based compensation for key personnel.

Next Steps

• James C. Momtazee's continued service on the BridgeBio Pharma, Inc. board of directors is required for the vesting of the granted RSUs and stock options.

Key Dates

Keywords

BridgeBio Pharma, BBIO, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership